
Amedisys (AMED) Stock Forecast & Price Target
Amedisys (AMED) Analyst Ratings
Bulls say
Amedisys Inc. demonstrated a positive financial trajectory with consolidated revenues of $598.1 million for 4Q24, reflecting a year-over-year increase of 4.8%. The Home Health segment showed growth in total visits of 5.2%, while the High Acuity Care segment reported a significant revenue increase of 37.3% year-over-year, indicating strong demand for home-based healthcare services. Additionally, the Hospice segment saw a net revenue per day growth of 2.8%, supporting a favorable outlook amid trends in both Medicare and non-Medicare revenue growth.
Bears say
Amedisys Inc experienced a year-over-year decline in Medicare revenues of -3.9%, highlighting underlying challenges in its primary Home Health segment, which saw a modest revenue increase of 5.0% but a significant drop in adjusted EBITDA by -5.0%. The company's overall financial performance was further hindered by a -7.5% miss in consolidated adjusted EBITDA, alongside negative adjustments in both Home Health and Hospice segments that fell short of projections by -3% and -4%, respectively. Additionally, a contraction in Hospice segment metrics—despite revenue growth—indicates potential long-term operational pressure, as reflected by the decreasing EBITDA margins across both key segments.
This aggregate rating is based on analysts' research of Amedisys and is not a guaranteed prediction by Public.com or investment advice.
Amedisys (AMED) Analyst Forecast & Price Prediction
Start investing in Amedisys (AMED)
Order type
Buy in
Order amount
Est. shares
0 shares